ESMO 2018 Congress coverage

Results of the JAVELIN Renal 101 trial indicate that patients with a new diagnosis of advanced renal cell carcinoma have better outcomes when treated with the combination of avelumab and axitinib than with sunitinib.

Progression-free survival is significantly improved with the use of maintenance olaparib in women with newly diagnosed FIGO stage III or IV ovarian cancer and a BRCA1/2 mutation, shows the placebo-controlled SOLO1 trial.

Results for the IMpassion130 trial support the combination of atezolizumab and nab-paclitaxel for the treatment of metastatic triple-negative breast cancer, especially among patients with programmed cell death ligand 1-positive disease.

Supplementing exemestane with the selective histone deacetylase inhibitor chidamide significantly prolongs the progression-free survival of women with hormone receptor-positive, HER2-negative advanced breast cancer, phase III trial findings indicate.

The latest results from the STAMPEDE trial do not show an additional overall survival benefit with radiotherapy for men undergoing androgen deprivation therapy with or without docetaxel for newly diagnosed metastatic prostate cancer.

A database analysis reported at the ESMO 2018 Congress in Munich, Germany, points to the feasibility of using immune checkpoint inhibitors in people living with HIV who develop cancer.